<?xml version="1.0" encoding="UTF-8"?>
<ref id="B8-pharmaceutics-10-00247" class="ref">
 <label class="label">8.</label>
 <element-citation publication-type="journal" class="element-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Oktay</surname>
    <given-names class="given-names">A.N.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Karakucuk</surname>
    <given-names class="given-names">A.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Ilbasmis</surname>
    <given-names class="given-names">T.S.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Celebi</surname>
    <given-names class="given-names">N.</given-names>
   </name>
  </person-group>
  <article-title class="article-title">Dermal flurbiprofen nanosuspensions: Optimization with design ofexperiment approach and in vitro evaluation</article-title>
  <source class="source">Eur. J. Pharm. Sci.</source>
  <year class="year">2018</year>
  <volume class="volume">122</volume>
  <fpage class="fpage">254</fpage>
  <lpage class="lpage">263</lpage>
  <pub-id pub-id-type="doi" class="pub-id">10.1016/j.ejps.2018.07.009</pub-id>
  <?supplied-pmid 29981401?>
  <pub-id pub-id-type="pmid" class="pub-id">29981401</pub-id>
 </element-citation>
</ref>
